Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Anika Therapeutics (ANIK) FCF Margin: 2009-2024

Historic FCF Margin for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to -1.94%.

  • Anika Therapeutics' FCF Margin rose 506.00% to 17.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.57%, marking a year-over-year increase of 151.00%. This contributed to the annual value of -1.94% for FY2024, which is 403.00% up from last year.
  • As of FY2024, Anika Therapeutics' FCF Margin stood at -1.94%, which was up 67.45% from -5.97% recorded in FY2023.
  • In the past 5 years, Anika Therapeutics' FCF Margin ranged from a high of 8.77% in FY2020 and a low of -5.97% during FY2023.
  • In the last 3 years, Anika Therapeutics' FCF Margin had a median value of -2.70% in 2022 and averaged -3.54%.
  • Its FCF Margin has fluctuated over the past 5 years, first slumped by 2,105bps in 2020, then soared by 403bps in 2024.
  • Anika Therapeutics' FCF Margin (Yearly) stood at 8.77% in 2020, then slumped by 657bps to 2.20% in 2021, then tumbled by 490bps to -2.70% in 2022, then slumped by 327bps to -5.97% in 2023, then spiked by 403bps to -1.94% in 2024.